CAMBRIDGE, Mass., Oct. 27 Ironwood Pharmaceuticals, Inc. today announced that Marsha Fanucci has joined its Board of Directors. Ms. Fanucci served at Millennium Pharmaceuticals, Inc. from 2000-2009 in a number of senior positions, including chief financial officer and senior vice president of strategy, vice president of finance and strategy, and vice president of corporate development and strategy. During her tenure as CFO, Ms. Fanucci led Millennium through a series of strategic focusing processes, advancing the company from an investment stage company to a profitable industry leader that was acquired by Takeda Pharmaceutical Company in 2008 for $8.8 billion. Previously, Ms. Fanucci was vice president of corporate development and strategy at Genzyme Corporation, and prior to that, vice president and director at Arthur D. Little, Inc.
(Logo: http://www.newscom.com/cgi-bin/prnh/20081006/NEM080ALOGO )
"We are thrilled to integrate Marsha's expertise into our board dynamic. Marsha shares with our other board members business savvy, an owner-orientation, and a strong commitment to fostering a culture with a high degree of integrity," said Peter Hecht, CEO of Ironwood. "We look forward to tapping into her deep leadership experience managing innovation and integrating corporate strategy, finance, and operations."
"I am excited to be joining Ironwood as the company strives to bring linaclotide to patients and advance its development pipeline," said Ms. Fanucci. "I look forward to working with the board and management team to build a great entrepreneurial pharmaceutical company."
Ms. Fanucci has a B.S. in pharmacy from West Virginia University Medical School and an M.B.A. from Northeastern University. She serves on the board of directors of Momenta Pharmaceuticals, where she chairs the Audit Committee.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (www.ironwoodpharma.com) is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. Linaclotide, the Company's first-in-class compound, is being evaluated in a confirmatory Phase 3 program for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation. Ironwood also has a growing pipeline of additional drug candidates in earlier stages of development. Ironwood has raised $306 million in private equity financing and is located in Cambridge, Massachusetts.
Contact: Susan Brady Corporate Communications 617.621.8304 email@example.com
SOURCE Ironwood Pharmaceuticals, Inc.